SEC Form 4 · accession 0001104659-18-059105
RHYTHM PHARMACEUTICALS, INC. · RYTM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leonardus H.T. Van der Ploeg
Officer — Chief Scientific Officer
Period of report
Sep 25, 2018
Accepted (ET)
Sep 27, 2018 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001649904
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 29, 2018 | G | 2,000 | $0.00 | D | 62,339 | D | |
| Common Stock | Sep 25, 2018 | M | 21,800 | $4.59 | A | 84,139 | D | |
| Common StockF3 | Sep 25, 2018 | S | 3,686 | $27.45 | D | 80,453 | D | |
| Common StockF4 | Sep 25, 2018 | S | 9,052 | $28.88 | D | 71,401 | D | |
| Common StockF5 | Sep 25, 2018 | S | 7,656 | $29.81 | D | 63,745 | D | |
| Common StockF6 | Sep 25, 2018 | S | 5,304 | $30.60 | D | 58,441 | D | |
| Common StockF7 | Sep 25, 2018 | S | 6,102 | $31.86 | D | 52,339 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F8 | $4.59 | Sep 25, 2018 | M | 21,800 | D | — | Nov 16, 2025 | Common Stock | 21,800 | 41,671 | D |
Explanation of responses
- F1Mr. Van der Ploeg is voluntarily reporting a gift transfer of shares of common stock.
- F2On September 25, 2018, Mr. Van der Ploeg sold 31,800 shares in multiple trades at prices ranging from $27.12 to $32.36 pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 (the "10b5-1 Plan").
- F3This transaction was executed in multiple trades at prices ranging from $27.12 to $27.88, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff (the "Staff"), the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $28.20 to $29.19, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $29.21 to $30.20, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $30.21 to $31.20, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F7This transaction was executed in multiple trades at prices ranging from $31.36 to $32.05, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F8The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015.